Advertisement

Franz H. Messerli, MD: A Conversation With the Editor

        Franz Messerli was born in Schwarzenburg, Switzerland, and grew up in this small town about 12 miles from Bern, the capital (Figure 1) . He was born in 1942, and graduated from the University of Bern Medical School in 1968. His internship and residency were in the Department of Medicine at the University Medical School in Bern, and he was awarded the MD degree from that university in 1971. In 1971, he volunteered as a medical delegate of the International Red Cross in Saigon, South Vietnam, for 6 months (Figure 2) . Returning to Bern, he did a 2-year cardiology fellowship in the Department of Cardiology in Bern, finishing in 1973. He then went to Montreal, Canada, for a 2-year research fellowship at Hotel Dieu Hospital in Montreal. Thereafter, he returned to Bern to direct the hypertension service of the Department of Medicine at the University Medical School. In 1976, he left Switzerland and moved to New Orleans, Louisiana, and the Ochsner Clinic Foundation, where he stayed for 28 years as Director of Clinical Hypertension and Clinical Professor of Medicine at Tulane University Medical School. In the fall of 2004, he left the Crescent City for the Big Apple, and is now Director of the Hypertension Program in the Division of Cardiology at St. Lukes-Roosevelt Hospital Corporation in New York City. Dr. Messerli has published more than 600 articles, mainly in peer-review medical journals, and he has written or edited 20 books or monographs. He has traveled extensively giving medical presentations and is one of the most popular speakers on the cardiovascular circuit. He is also a nice guy and a friend.
        Figure thumbnail gr1
        Figure 1The first tricycle.
        Figure thumbnail gr2
        Figure 2Examining a patient in a POW camp in Da Nang, South Vietnam.
        To read this article in full you will need to make a payment

        Purchase one-time access:

        Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
        One-time access price info
        • For academic or personal research use, select 'Academic and Personal'
        • For corporate R&D use, select 'Corporate R&D Professionals'

        Subscribe:

        Subscribe to American Journal of Cardiology
        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect

        Best Publications as Selected by FHM

          • Messerli F.H.
          • Cottier P.
          Quality of treatment with anticoagulants in acute myocardial infarction (in German).
          Schweiz Med Wschr. 1970; 100: 2064-2071
          • Messerli F.H.
          • Genest J.
          • Nowaczynski W.
          • Kuchel O.
          • Honda M.
          • Latour Y.
          • Dumont G.
          Splanchnic blood flow in essential hypertension and in hypertension and in hypertensive patients with renal artery stenosis.
          Circulation. 1975; 51: 1114-1119
          • Messerli F.H.
          • Genest J.
          • Nowaczynski W.
          • Kuchel O.
          • Cartier P.
          • Rojo-Ortega J.M.
          • Honda M.
          • Boucher R.
          Hypertension with renal artery stenosis.
          Am J Cardiol. 1975; 36: 702-707
          • Messerli F.H.
          • Kuchel O.
          • Nowaczynski W.
          • Seth K.
          • Honda M.
          • Kubo S.
          • Boucher R.
          • Tolis G.
          • Genest J.
          Mineralocorticoid secretion in essential hypertension with normal and low plasma renin activity.
          Circulation. 1976; 53: 406-410
          • Messerli F.H.
          • Kuchel O.
          • Hamet P.
          • Tolis G.
          • Guthrie G.
          • Fraysse J.
          • Genest J.
          Plasma adenosine 3, 5-monophosphate response to isoproterenol and glucagon in labile (borderline) hypertension.
          Circ Res. 1976; 38: 42-47
          • Messerli F.H.
          • Nowaczynski W.
          • Honda M.
          • Genest
          • Boucher J.
          • Kuchel O.
          • Rojo-Ortega J.M.
          Effects of angiotensin II on steroid metabolism and hepatic blood flow.
          Circ Res. 1977; 40: 204-207
          • Messerli F.H.
          • DeCarvalho J.G.R.
          • Christie B.
          • Frohlich E.D.
          Systemic and regional hemodynamics in low, normal and high cardiac output borderline hypertension.
          Circulation. 1978; 58: 441-448
          • Messerli F.H.
          • Frohlich E.D.
          High blood pressure.
          Arch Intern Med. 1979; 139: 682-687
          • Messerli F.H.
          • DeCarvalho J.G.R.
          • Christie B.
          • Frohlich E.D.
          Essential hypertension in black and white subjects.
          Am J Med. 1979; 67: 27-31
          • Messerli F.H.
          • Frohlich E.D.
          • Dreslinski G.R.
          • Suarez D.H.
          • Aristimuno G.G.
          Serum uric acid in essential hypertension. An indicator of renal vascular involvement.
          Ann Intern Med. 1980; 93: 817-821
          • Messerli F.H.
          • Christie B.
          • DeCarvalho J.G.R.
          • Aristimuno G.G.
          • Suarez D.H.
          • Dreslinski G.R.
          • Frohlich E.D.
          Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion and plasma renin activity.
          Arch Intern Med. 1981; 141: 81-85
          • Messerli F.H.
          • Frohlich E.D.
          • Suarez D.H.
          • Reisin E.
          • Dreslinski G.R.
          • Dunn F.H.
          • Cole F.E.
          Borderline hypertension.
          Circulation. 1981; 64: 760-764
          • Messerli F.H.
          • Finn M.
          • MacPhee A.A.
          Pheochromocytoma of the urinary bladder.
          JAMA. 1982; 247: 1863-1864
          • Messerli F.H.
          Cardiovascular effects of obesity and hypertension.
          Lancet. 1982; 2: 1165-1168
          • Messerli F.H.
          • Sungaard-Riise K.
          • Reisin E.
          • Dreslinski G.R.
          • Dunn F.G.
          • Frohlich E.D.
          Disparate cardiovascular effects of obesity and arterial hypertension.
          Am J Med. 1983; 74: 808-812
          • Messerli F.H.
          • Ventura H.O.
          • Glade L.B.
          • Sungaard-Riise K.
          • Dunn F.H.
          • Frohlich E.D.
          Essential hypertension in the elderly.
          Lancet. 1983; 2: 983-986
          • Messerli F.H.
          • Sungaard-Riise K.
          • Reisin E.
          • Dreslinski G.R.
          • Ventura H.O.
          • Oigman W.
          • Frohlich E.D.
          Dimorphic cardiac adaptation to obesity and essential hypertension.
          Ann Intern Med. 1983; 99: 757-761
          • Messerli F.H.
          • Sungaard-Riise K.
          • Ventura H.O.
          • Dunn F.G.
          • Oigman W.
          • Frohlich E.D.
          Clinical hemodynamic determinants of left ventricular dimensions.
          Arch Intern Med. 1984; 144: 477-481
          • Messerli F.H.
          • Ventura H.O.
          • Elizardi D.J.
          • Dunn F.G.
          • Frohlich E.D.
          Hypertension and sudden death.
          Am J Med. 1984; 77: 18-22
          • Messerli F.H.
          Obesity in hypertension.
          Am J Med. 1984; 77: 1077-1082
          • Messerli F.H.
          • Ventura H.O.
          • Amodeo C.
          Osler’s maneuver and pseudohypertension.
          N Engl J Med. 1985; 312: 1548-1551
          • Messerli F.H.
          Cardiopathy of obesity—a not-so-Victorian disease (editorial).
          N Engl J Med. 1986; 314: 378-379
          • Messerli F.H.
          Osler’s maneuver, pseudohypertension, and true hypertension in the elderly.
          Am J Med. 1986; 80: 906-910
          • Messerli F.H.
          • Garavaglia G.E.
          • Schmieder R.E.
          • Sungaard-Riise K.
          • Nunez B.D.
          • Amodeo C.
          Disparate cardiovascular findings in men and women with essential hypertension.
          Ann Intern Med. 1987; 107: 158-161
          • Messerli F.H.
          • Nunez B.D.
          • Ventura H.O.
          • Snyder D.W.
          Overweight and sudden death.
          Arch Intern Med. 1987; 147: 1725-1728
        1. Messerli FH. Liquid formula diet can be hazardous to heart (letter). New York Times CXXXVIII(47,711):26, December 6, 1988.

          • Messerli F.H.
          • Nunez B.D.
          • Nunez M.M.
          • Garavaglia G.E.
          • Schmieder R.E.
          • Ventura H.O.
          Hypertension and sudden death.
          Arch Intern Med. 1989; 149: 1263-1267
          • Messerli F.H.
          Antihypertensive therapy—going to the heart of the matter.
          Circulation. 1990; 81: 1128-1135
          • Messerli F.H.
          Cardioprotection—not all calcium antagonists are created equal (editorial).
          Am J Cardiol. 1990; 66: 855-856
          • Messerli F.H.
          This day 50 years ago.
          N Engl J Med. 1995; 332: 1038-1039
          • Opie L.H.
          • Messerli F.H.
          Editorial.
          Circulation. 1995; 92: 1068-1073
          • Messerli F.H.
          Are calcium antagonists safe?.
          Lancet. 1995; 346: 767-768
          • Messerli F.H.
          Case-control study, meta-analysis, and bouillabaisse.
          Ann Intern Med. 1995; 123: 888-889
          • Messerli F.H.
          Whatever happened to the calcium antagonist controversy? (editorial).
          J Am Coll Cardiol. 1996; 28: 12-13
          • Messerli F.H.
          • Weber M.A.
          • Brunner H.R.
          Angiotensin II receptor inhibition - a new therapeutic principle.
          Arch Intern Med. 1996; 156: 1957-1965
          • Grossman E.
          • Messerli F.H.
          • Grodzicki T.
          • Kowey P.
          Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?.
          JAMA. 1996; 276: 1328-1331
          • Messerli F.H.
          “Cardioprotection”—not all calcium antagonists are created equal.
          Am J Cardiol. 1997; 79: 788-789
          • Messerli F.H.
          • Schmieder R.E.
          • Weir M.R.
          Salt.
          Arch Intern Med. 1997; 157: 2449-2452
          • Messerli F.H.
          • Grossman E.
          Do calcium antagonists increase the risk for malignancies? (editorial).
          J Am Coll Cardiol. 1998; 31: 809-810
          • Messerli F.H.
          • Grossman E.
          • Goldbourt U.
          Are β-blockers efficacious as first-line therapy for hypertension in the elderly?.
          JAMA. 1998; 279: 1903-1907
          • Messerli F.H.
          • Grossman E.
          The calcium antagonist controversy.
          Am J Cardiol. 1998; 82: 35R-39R
          • Grossman E.
          • Messerli F.H.
          • Goldbourt U.
          Does diuretic therapy increase the risk of renal cell carcinoma?.
          Am J Cardiol. 1999; 83: 1090-1093
          • Messerli F.H.
          Outcome studies—are all antihypertensive drugs created equal? (editorial).
          J Am Coll Cardiol. 1999; 34: 1652-1653
          • Messerli F.H.
          • Grossman E.
          The use of sublingual nifedipine—a continuing concern.
          Arch Intern Med. 1999; 159: 2259-2260
          • Messerli F.H.
          And losartan was no better than placebo (editorial).
          J Human Hypertens. 1999; 13: 649-650
          • Messerli F.H.
          Implications of discontinuation of doxazosin arm of ALLHAT (editorial).
          Lancet. 2000; 355: 863-864
          • Messerli F.H.
          • Nussberger J.
          Vasopeptidase inhibition and angio-oedema.
          Lancet. 2000; 356: 608-609
          • Messerli F.H.
          • Schmieder R.E.
          Salt and hypertension.
          Arch Intern Med. 2001; 161: 505-506
          • Messerli F.H.
          When in France (letter).
          New York Times Magazine. May 5, 2002; : 14
          • Messerli F.H.
          • Hanley D.F.
          • Gorelick P.
          Blood pressure control in stroke patients.
          Neurology. 2002; 59: 23-25
          • Messerli F.H.
          The LIFE study.
          Eur Heart J. 2003; 24: 487-489
          • Messerli F.H.
          • Weber M.A.
          ALLHAT—all hit or all miss? Key questions still remain (editorial).
          Am J Cardiol. 2003; 92: 280-281
          • Messerli F.H.
          • Beevers D.G.
          • Franklin S.S.
          • Pickering F.G.
          B-blockers in hypertension the emperor has no clothes.
          Am J Hypertens. 2003; 16: 870-873
          • Messerli F.H.
          Of millimeterology and cannibalism.
          Am Heart J. 2003; 146: 568-569
          • Messerli F.H.
          ALLHAT, or the soft science of the secondary end point.
          Ann Intern Med. 2003; 139: 777-780
          • Messerli F.H.
          • Grossman E.
          • Lever A.F.
          Do thiazide diuretics provide specific protection against strokes?.
          Arch Intern Med. 2003; 163: 2557-2560
          • Messerli F.H.
          TIMPs, MMPs and cardiovascular disease (editorial).
          Eur Heart J. 2004; 25: 1475-1476
          • Messerli F.H.
          • Grossman E.
          • Leonetti G.
          Antihypertensive therapy and new onset diabetes.
          J Hypertens. 2004; 22: 1845-1847